Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
Richard S P HuangXinyan LiJames HaberbergerEthan SokolEric SeversonDaniel L DuncanAmanda HemmerichClaire EdgerlyErik WilliamsJulia ElvinJo-Anne VergilioJonathan Keith KillianDouglas LinMatthew HiemenzJinpeng XiaoDeborah McEwanOliver HolmesNatalie DanzigerRachel ErlichGarrett FramptonMichael B CohenKimberly McGregorPrasanth ReddyDawn CardeiroRachel AnhornJeffrey VenstromBrian AlexanderCharlotte BrownLajos PusztaiJeffrey S RossShakti H RamkissoonPublished in: The oncologist (2020)
This integrated programmed death-ligand 1 immunohistochemistry and comprehensive genomic profiling methodology identified 32% of the tested patients as eligible for at least one of the two new Food and Drug Administration-approved therapies, atezolizumab or alpelisib, and an additional 61.2% (191/312) had other biomarker-guided potential therapeutic options. These findings suggest new research opportunities to evaluate the predictive utility of other commonly seen PIK3CA mutations in hormone receptor-positive breast cancers and to standardize tumor mutation burden cutoffs to evaluate its potentially predictive role in triple-negative breast cancer.